View Item 

Show simple item record

Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation
dc.contributor.authorSharma, Pratima
dc.contributor.authorMoore, Kevin
dc.contributor.authorGanger, Daniel
dc.contributor.authorGrewal, Priya
dc.contributor.authorBrown, Robert S.
dc.date.accessioned2020-10-01T23:30:48Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-10-01T23:30:48Z
dc.date.issued2020-10
dc.identifier.citationSharma, Pratima; Moore, Kevin; Ganger, Daniel; Grewal, Priya; Brown, Robert S. (2020). "Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation." Liver Transplantation 26(10): 1328-1336.
dc.identifier.issn1527-6465
dc.identifier.issn1527-6473
dc.identifier.urihttps://hdl.handle.net/2027.42/162755
dc.publisherWiley Periodicals, Inc.
dc.titleRole of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelSurgery and Anesthesiology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/162755/2/lt25834.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/162755/1/lt25834_am.pdfen_US
dc.identifier.doi10.1002/lt.25834
dc.identifier.sourceLiver Transplantation
dc.identifier.citedreferenceGinès A, Fernández‐Esparrach G, Monescillo A, Vila C, Domènech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002 ‐ 1010.
dc.identifier.citedreferenceSharma P, Goodrich NP, Zhang M, Guidinger MK, Schaubel DE, Merion RM. Short‐term pretransplant renal replacement therapy and renal nonrecovery after liver transplantation alone. Clin J Am Soc Nephrol 2013; 8: 1135 ‐ 1142.
dc.identifier.citedreferenceBernardi M, Angeli P, Claria J, Moreau R, Gines P, Jalan R, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut 2020; 69: 1127 ‐ 1138.
dc.identifier.citedreferenceFernández J, Angeli P, Trebicka J, Merli M, Gustot T, Alessandria C, et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2020; 18: 963 ‐ 973.
dc.identifier.citedreferenceFernández J, Clària J, Amorós A, Aguilar F, Castro M, Casulleras M, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology 2019; 157: 149 ‐ 162.
dc.identifier.citedreferenceLuca A, Garciá‐Pagán JC, Bosch J, Feu F, Jiménez W, Ginés A, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology 1995; 22: 753 ‐ 758.
dc.identifier.citedreferenceSalerno F, Navickis RJ, Wilkes MM. Albumin treatment regimen for type 1 hepatorenal syndrome: a dose‐response meta‐analysis. BMC Gastroenterol 2015; 15: 167.
dc.identifier.citedreferenceSingh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012; 56: 1293 ‐ 1298.
dc.identifier.citedreferenceSharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008; 103: 1689 ‐ 1697.
dc.identifier.citedreferenceAngeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, et al.; for European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406 ‐ 460.
dc.identifier.citedreferenceSalerno F, Cazzaniga M, Gobbo G. Pharmacological treatment of hepatorenal syndrome: a note of optimism. J Hepatol 2007; 47: 729 ‐ 731.
dc.identifier.citedreferenceArora V, Maiwall R, Rajan V, Jindal A, Muralikrishna Shasthry S, Kumar G, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology 2020; 71: 600 ‐ 610.
dc.identifier.citedreferenceCavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology 2016; 63: 983 ‐ 992.
dc.identifier.citedreferencePiano S, Vettore E, Tonon M, Gambino C, Romano A, Boccagni P, et al. Response to treatment with terlipressin and albumin improves post liver transplant outcomes in patients with hepatorenal syndrome. Hepatology 2019; 70: 239.
dc.identifier.citedreferenceWong F, Leung W, Al Beshir M, Marquez M, Renner EL. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transpl 2015; 21: 300 ‐ 307.
dc.identifier.citedreferenceSharma P, Goodrich NP, Schaubel DE, Guidinger MK, Merion RM. Patient‐specific prediction of ESRD after liver transplantation. J Am Soc Nephrol 2013; 24: 2045 ‐ 2052.
dc.identifier.citedreferenceOPTN. Simultaneous Liver Kidney (SLK) Allocation Policy. https://optn.transplant.hrsa.gov/media/1192/0815‐12_SLK_Allocation.pdf; Accessed February 17, 2020.
dc.identifier.citedreferenceSharma P, Schaubel DE, Guidinger MK, Goodrich NP, Ojo AO, Merion RM. Impact of MELD‐based allocation on end‐stage renal disease after liver transplantation. Am J Transplant 2011; 11: 2372 ‐ 2378.
dc.identifier.citedreferenceAllegretti AS, Parada XV, Eneanya ND, Gilligan H, Xu D, Zhao S, et al. Prognosis of patients with cirrhosis and AKI who initiate RRT. Clin J Am Soc Nephrol 2018; 13: 16 ‐ 25.
dc.identifier.citedreferenceOPTN. Transplant by donor type. https://optn.transplant.hrsa.gov/data/view‐data‐reports/national‐data/#. Accessed February 17, 2020.
dc.identifier.citedreferenceOPTN. Current U.S. Waiting List. https://optn.transplant.hrsa.gov/data/view‐data‐reports/national‐data/#. Accessed February 17, 2020.
dc.identifier.citedreferenceWiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al.; for United Network for Organ Sharing Liver Disease Severity Score Committee. Model for End‐Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91 ‐ 96.
dc.identifier.citedreferenceSharma P, Schaubel DE, Sima CS, Merion RM, Lok ASF. Re‐weighting the model for end‐stage liver disease score components. Gastroenterology 2008; 135: 1575 ‐ 1581.
dc.identifier.citedreferenceGonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006; 6: 2651 ‐ 2659.
dc.identifier.citedreferenceSharma P, Schaubel DE, Guidinger MK, Merion RM. Effect of pretransplant serum creatinine on the survival benefit of liver transplantation. Liver Transpl 2009; 15: 1808 ‐ 1813.
dc.identifier.citedreferenceNadim MK, Sung RS, Davis CL, Andreoni KA, Biggins SW, Danovitch GM, et al. Simultaneous liver‐kidney transplantation summit: current state and future directions. Am J Transplant 2012; 12: 2901 ‐ 2908.
dc.identifier.citedreferenceGarcia‐Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064 ‐ 2077.
dc.identifier.citedreferenceAngeli P, Garcia‐Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol 2019; 71: 811 ‐ 822.
dc.identifier.citedreferenceAngeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut 2015; 64: 531 ‐ 537.
dc.identifier.citedreferenceBoyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O’Leary JG, et al.; for REVERSE Study Investigators. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology 2016; 150: 1579 ‐ 1589.
dc.identifier.citedreferenceCavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, et al.; for Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology 2015; 62: 567 ‐ 574.
dc.identifier.citedreferenceMartin‐Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352 ‐ 1359.
dc.identifier.citedreferenceMoreau R. Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol 2002; 17: 739 ‐ 747.
dc.identifier.citedreferenceSanyal AJ, Boyer T, Garcia‐Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al.; for Terlipressin Study Group. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360 ‐ 1368.
dc.identifier.citedreferenceWang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta‐analysis. Medicine (Baltimore) 2018; 97: e0431.
dc.identifier.citedreferenceWong F, Curry MP, Reddy KR, Rubin RA, Porayko MK, Gonzalez SA, et al. The CONFIRM study: a North American randomized controlled trial (RCT) of terlipressin plus albumin for the treatment of hepatorenal syndrome type 1 (HRS‐1). Hepatology 2019; 70: LB‐5.
dc.identifier.citedreferenceGinès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279 ‐ 1290.
dc.identifier.citedreferenceD’Amico G, Garcia‐Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217 ‐ 231.
dc.identifier.citedreferenceFede G, D’Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012; 56: 810 ‐ 818.
dc.identifier.citedreferenceMoreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003; 37: 233 ‐ 243.
dc.identifier.citedreferenceBernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 2015; 63: 1272 ‐ 1284.
dc.identifier.citedreferenceMartin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533 ‐ 541.
dc.identifier.citedreferenceMøller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int 2018; 38: 570 ‐ 580.
dc.identifier.citedreferenceSchrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151 ‐ 1157.
dc.identifier.citedreferenceSola E, Ginès P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010; 53: 1135 ‐ 1145.
dc.identifier.citedreferenceAcevedo J, Fernández J, Prado V, Silva A, Castro M, Pavesi M, et al. Relative adrenal insufficiency in decompensated cirrhosis: relationship to short‐term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology 2013; 58: 1757 ‐ 1765.
dc.identifier.citedreferenceClària J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute‐on‐chronic liver failure. Hepatology 2016; 64: 1249 ‐ 1264.
dc.identifier.citedreferenceTrebicka J, Amoros A, Pitarch C, Titos E, Alcaraz‐Quiles J, Schierwagen R, et al. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis. Front Immunol 2019; 10: 476.
dc.identifier.citedreferenceSolé C, Solà E, Morales‐Ruiz M, Fernàndez G, Huelin P, Graupera I, et al. Characterization of inflammatory response in acute‐on‐chronic liver failure and relationship with prognosis. Sci Rep 2016; 6: 32341.
dc.identifier.citedreferenceDavenport A, Sheikh MF, Lamb E, Agarwal B, Jalan R. Acute kidney injury in acute‐on‐chronic liver failure: where does hepatorenal syndrome fit? Kidney Int 2017; 92: 1058 ‐ 1070.
dc.identifier.citedreferenceArroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164 ‐ 176.
dc.identifier.citedreferenceSalerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310 ‐ 1318.
dc.identifier.citedreferenceBoyer TD, Sanyal AJ, Garcia‐Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2011; 55: 315 ‐ 321.
dc.identifier.citedreferenceRodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, et al. Terlipressin and albumin for type‐1 hepatorenal syndrome associated with sepsis. J Hepatol 2014; 60: 955 ‐ 961.
dc.identifier.citedreferenceKoppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 1969; 280: 1367 ‐ 1371.
dc.identifier.citedreferenceNorthup PG, Argo CK, Bakhru MR, Schmitt TM, Berg CL, Rosner MH. Pretransplant predictors of recovery of renal function after liver transplantation. Liver Transpl 2009; 16: 440 ‐ 446.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
lt25834_am.pdf
Size:
286.8KB
Format:
PDF
View/Open
Name:
lt25834.pdf
Size:
522.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.